Your Source for Venture Capital and Private Equity Financings

Ring Therapeutics Scores $86.5M Series C

CAMBRIDGE, MA, Ring Therapeutics today announced that it raised $86.5 million in Series C funding.
Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize gene therapy with its commensal virome platform, today announced that it raised $86.5 million in Series C funding, bringing its total funds raised to date to $230 million. Investors included Alexandria Venture Investments; Altitude Life Science Ventures; CJ Investment; Ring's founder, Flagship Pioneering; Invus; Kyowa Kirin Co., Ltd; Partners Investment; funds and accounts advised by T. Rowe Price Associates, Inc.; UPMC Enterprises, and others including all of Ring's existing institutional shareholders.

Ring Therapeutics is revolutionizing the gene therapy and nucleic acid medicine space by harnessing the most abundant and diverse member of the human commensal virome, anelloviruses. The company developed the Anellogy™ platform which focuses on anelloviruses to potentially treat a broad range of diseases. Through harnessing the unique properties of these commensal viruses, the Anellogy™ platform generates diverse vectors that exhibit both tissue-specific tropism and the potential to be re-dosed. Ring Therapeutics, founded by Flagship Pioneering in 2017, aims to develop and further expand its portfolio by leveraging its platform to unlock the full potential of gene therapy and nucleic acid medicines, enabling a variety of mechanisms that successfully deliver therapeutic cargo to unreachable organs and tissues.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000 startups and 5,000 VC investors

Featured Reading